VACCINE DEVELOPMENT
Our Approach
We are on a mission to address the pressing need for a novel prophylactic vaccine against Group B Streptococcus (GBS). Our lead candidate AlpN GBS is being tested in the clinic for use in pregnancy and in older people.
Our goal is to develop a vaccine that:
Protects against adverse pregnancy outcomes.
Protects the fetus in utero and newborns for up to 3 months after delivery.
Protects non-pregnant adults against GBS.
Alleviates the need for excessive use of antibiotics.
OUR SCIENCEAbout our vaccine
Our novel protein-only vaccine is based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS - the Alpha-like protein family (AlpN).
About the Alp-family
There are six GBS Alp variants: Alpha C (AlpC), Rib, Alp1, Alp2, Alp3, and Alp4, of which Alp4 is extremely rare.
The C-terminal domain of the Alp proteins contains a cell wall-anchoring motif and the N-terminal domain protrudes from GBS’ polysaccharide capsule and is functionally active. Their extracellular exposure, combined with the exceptionally broad coverage of clinical isolates, makes Alp N-terminal domains (Alp-Ns) highly relevant as vaccine candidates.
Why an Alp approach
We believe our approach has the potential to deliver a vaccine with broad coverage and protection.
Our lead vaccine candidate, AlpN GBS, consists of two fusion proteins each containing two Alp N-terminal domains: GBS-NN (containing RibN and AlpCN) & GBS-NN2 (containing Alp1N and Alp2/3N) which are the most prevalent Alp serotypes and cover >99% of clinical GBS isolates.
Learn more
Please click the links below to learn more about GBS, our product pipeline, and clinical trials.
